For decades, the advice to take folic acid before and during early pregnancy has rested on remarkably strong epidemiological evidence paired with a frustratingly incomplete mechanistic picture. Understanding exactly how folate prevents neural tube defects matters enormously — not only for refining supplementation strategies but for explaining why a meaningful fraction of NTDs remain resistant to folic acid intervention at all.
Working in a Xenopus (frog embryo) model with pax3 knockdown — a well-validated system for folic acid–rescuable neural tube defects — researchers identified a previously unrecognized enzymatic bridge between vitamin B9 metabolism and retinoic acid (RA) signaling. The key player is ALDH1L1 (formyl tetrahydrofolate dehydrogenase), an enzyme that metabolizes folate intermediates. Crucially, the team demonstrated that ALDH1L1 can directly convert retinaldehyde to retinoic acid, meaning it moonlights as a retinoid-processing enzyme. Folic acid upregulates aldh1l1 gene expression, boosting RA biosynthesis; CRISPR/Cas9-mediated knockdown of ALDH1L1 activity completely abolished folic acid's protective effect. Retinoic acid or its precursors alone were sufficient to rescue the NTDs in this model, and the same pathway appears relevant to alcohol-induced fetal malformations. At the cellular level, insufficient RA signaling permitted neural plate precursor overproliferation and pathological neural tube expansion — a mechanism that folic acid, through ALDH1L1-driven RA production, normalizes.
This finding reframes folic acid not as acting directly on DNA methylation or one-carbon metabolism to close the neural tube, but as a regulator of retinoic acid availability — a signaling molecule already known to be indispensable for neural development. It also offers a plausible molecular explanation for folic acid–resistant NTDs: impaired ALDH1L1 activity or disrupted RA signaling downstream could render supplementation ineffective. The Xenopus model is well-regarded but not human; translation requires validation in mammalian systems. Still, the identification of human ALDH1L1 as a functional retinaldehyde dehydrogenase substantially strengthens cross-species relevance. This is a genuinely paradigm-shifting mechanistic advance in one of reproductive medicine's most established public health interventions.